Arcturus Therapeutics Statistics
Want to see ARCT full AI Analyst Report?
Arcturus Therapeutics (ARCT) Stock Statistics & Valuation Metrics
Total Valuation
Arcturus Therapeutics has a market cap or net worth of $240.96M. The enterprise value is $226.39M.
- Market Cap
- $240.96M
- Enterprise Value
- $226.39M
Share Statistics
Arcturus Therapeutics has 28,822,514 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 28,822,514
- Owned by Insiders
- 7.16%
- Owned by Institutions
- 85.14%
Financial Efficiency
Arcturus Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -31.36%.
- Return on Equity (ROE)
- -0.31
- Return on Assets (ROA)
- -0.24
- Return on Invested Capital (ROIC)
- -31.36%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 616.71K
- Profits Per Employee
- -603.51K
- Employee Count
- 109
- Asset Turnover
- 0.25
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Arcturus Therapeutics is -2.70. Arcturus Therapeutics’s PEG ratio is 0.10.
- PE Ratio
- -2.70
- PS Ratio
- 9.66
- PB Ratio
- 1.41
- Price to FCF
- -3.84
- Price to Operating Cash Flow
- -3.81
- PEG Ratio
- 0.10
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 67.22M and earned -65.78M in profits. Earnings per share was -2.40.
- Revenue
- 67.22M
- Gross Profit
- 64.20M
- Operating Income
- -74.95M
- Pretax Income
- -65.78M
- Net Income
- -65.78M
- EBITDA
- -62.76M
- Earnings Per Share (EPS)
- -2.40
Cash Flow
In the last 12 months, operating cash flow was -62.48M and capital expenditures -189,660, giving a free cash flow of -62.67M billion.
- Operating Cash Flow
- -62.48M
- Free Cash Flow
- -62.67M
- Free Cash Flow per Share
- -2.20
Dividends & Yields
Arcturus Therapeutics pays an annual dividend of $0.06, resulting in a dividend yield of ―
- Dividend Per Share
- $0.06
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -26.01%
- Earnings Yield
- -36.69%
Stock Price Statistics
- Beta
- 2.26
- 52-Week Price Change
- 7.59%
- 50-Day Moving Average
- 12.43
- 200-Day Moving Average
- 9.15
- Relative Strength Index (RSI)
- 36.96
- Average Volume (3m)
- 988.60K
Important Dates
Arcturus Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- Jan 08, 2013
Financial Position
Arcturus Therapeutics as a current ratio of 6.64, with Debt / Equity ratio of 11.68%
- Current Ratio
- 6.64
- Quick Ratio
- 6.64
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.28
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Arcturus Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Arcturus Therapeutics EV to EBITDA ratio is -1.01, with an EV/FCF ratio of -1.24.
- EV to Sales
- 3.13
- EV to EBITDA
- -1.01
- EV to Free Cash Flow
- -1.24
- EV to Operating Cash Flow
- -1.25
Balance Sheet
Arcturus Therapeutics has $184.82M in cash and marketable securities with $21.86M in debt, giving a net cash position of $162.95M billion.
- Cash & Marketable Securities
- $184.82M
- Total Debt
- $21.86M
- Net Cash
- $162.95M
- Net Cash Per Share
- $5.65
- Tangible Book Value Per Share
- $5.93
Margins
Gross margin is 97.36%, with operating margin of -384.08%, and net profit margin of -349.71%.
- Gross Margin
- 97.36%
- Operating Margin
- -384.08%
- Pretax Margin
- -349.73%
- Net Profit Margin
- -349.71%
- EBITDA Margin
- -308.66%
- EBIT Margin
- -316.61%
Analyst Forecast
The average price target for Arcturus Therapeutics is $21.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $21.38
- Price Target Upside
- 155.68% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- -74.84%
- EPS Growth Forecast
- -25.04%
Scores
- Smart Score
- 9
- AI Score
- 47

